IPASS
Non-invasive measurement of Intracranial Pressure (ICP)
Pilot ValidationActive
Key Facts
Indication
Non-invasive measurement of Intracranial Pressure (ICP)
Phase
Pilot Validation
Status
Active
Company
About CranioSense
CranioSense is tackling a critical unmet need in neurology and emergency medicine: the non-invasive measurement of intracranial pressure (ICP). The current gold standard requires drilling into the skull, limiting its use to only the most critical 2% of TBI cases. The company's IPASS platform uses a forehead patch and clip-on sensors to provide a rapid ICP reading, potentially enabling earlier intervention for a vastly larger patient population. With clinical validation studies ongoing, CranioSense is positioned to disrupt the standard of care in neurocritical monitoring.
View full company profile